Breakthrough device reimbursement rule on the rocks
Despite industry outcry, new data question how relevant the rule would have been anyway.
Medtronic bows to the inevitable
Paying $1.1bn for Heartware five years ago was not the company’s smartest move.
Medtronic’s Hugo still a long way from victor
The world’s biggest medtech expects great things from its new surgical robot, but its best shot at leading a market with a new product remains renal denervation.
The future of renal denervation
The pivotal trial of Medtronic’s hypertension device came out more than a year ago, yet the company has still not sought approval.
Aortic opportunity remains narrow for Abbott
Abbott’s latest aortic valve launch is unlikely to gain it a meaningful slice of the market; meanwhile, Edwards’ attention has switched to tricuspid.
